IP Library Granted Patent US 7,078,417
Granted Patent B2
US 7,078,417 · App. 10/473,372 · Granted Jul 18, 2006

Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines with adenosine receptor-binding activity and their use as cardiovascular preparations

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,078,417
App. No.
10/473,372
Granted
Jul 18, 2006
Kind
B2
Abstract

This application relates to pyridine derivatives having the general structure in which the several variables are as defined in the specification and claims, and to a process for preparing these compounds, a pharmacutical composition containing such compounds, and a method for using these materials for treatment of stable and unstable angina pectoris and atrial fibrillation.

Claims (53)

1. A compound of the formula (I)

in which

R 1 and R 2 are attached to adjacent phenyl ring atoms and together with the two ring carbon atoms form a 5- or 6-membered saturated or partially unsaturated ring which may contain one or two oxygen atoms and which may be mono- or disubstituted, independently of one another, by (C 1 –C 4 )-alkyl which may be substituted by hydroxyl, (C 1 –C 4 )-alkoxy or phenyl; cyano; halogen; or oxo;

R 3 represents (C 1 –C 8 )-alkyl which may be substituted up to three times, independently of one another, by hydroxyl, (C 1 –C 4 )-alkoxy, (C 3 –C 7 )-cycloalkyl, (C 2 –C 4 )-alkenyl, (C 2 –C 4 )-alkynyl, halogen or (C 6 –C 10 )-aryloxy; (C 6 –C 10 )-aryl which may be substituted up to three times, independently of one another, by halogen, nitro, (C 1 –C 4 )-alkoxy, carboxyl, (C 1 –C 4 -alkoxycarbonyl or mono- or di-(C 1 –C 4 )-alkylamino; (C 1 –C 8 )-alkoxy which may be substituted by hydroxyl, (C 1 –C 4 )-alkoxy, (C 3 –C 6 )-cycloalkyl, (C 2 –C 4 )-alkenyl, (C 6 –C 10 )-aryl, 5- to 10-membered heteroaryl having up to three heteroatoms from the group consisting of N, O and/or S, (C 6 –C 10 )-aryloxy, halogen, cyano, (C 1 –C 4 )-alkoxycarbonyl, amino or mono- or di-(C 1 –C 4 )-alkylamino; hydrogen; hydroxyl; halogen; nitro; cyano; or —NH—C(O)—R 5 ;

 in which

R 5 represents (C 1 –C 8 )-alkyl, which may be substituted by hydroxyl or (C 1 –C 4 )-alkoxy; or (C 3 –C 7 )-cycloalkyl or (C 6 –C 10 )-aryl, which may be substituted up to three times, independently of one another, by halogen, nitro, (C 1 –C 4 )-alkoxy, carboxyl, (C 1 –C 4 )-alkoxycarbonyl or mono- or di-(C 1 –C 4 )-alkylamino, and

R 4 represents (C 2 –C 4 )-alkenyl, (C 3 –C 7 )-cycloalkyl or (C 1 –C 8 )-alkyl, where alkyl may be substituted up to three times, independently of one another, by halogen, trifluoromethyl, trifluoromethylthio, (C 3 –C 7 )-cycloalkyl, hydroxyl, —CO—NH—R 6 , (C 1 –C 4 )-alkoxy, (C 1 –C 4 -alkoxycarbonyl, (C 2 –C 4 )-alkenyl, (C 6 –C 10 ))-aryl or 5- to 10-membered heteroaryl having up to three heteroatoms and/or hetero chain members selected from the group consisting of N, NO(N oxide), O and S,

 where

aryl and heteroaryl may be substituted up to three times, independently of one another, by halogen; trifluoromethyl; (C 1 –C 4 )-alkyl which may be substituted by carboxyl or (C 1 –C 4 )-alkoxycarbonyl; (C 1 –C 4 )-alkoxy; carboxyl; (C 1 –C 4 )-alkoxycarbonyl; amino; mono- or di-(C 1 –C 4 )-alkylamino; nitro; cyano; or hydroxyl; and

R 6 represents hydrogen; (C 1 –C 8 )-alkyl which may be substituted by hydroxyl or (C 1 –C 4 )-alkoxy; or (C 3 –C 7 )-cycloalkyl or (C 6 –C 10 )-aryl which may be substituted up to three times, independently of one another, by halogen, nitro, (C 1 –C 4 )-alkoxy, carboxyl, (C 1 –C 4 )-alkoxycarbonyl or mono- or di-(C 1 –C 4 )-alkylamino;

or a salt, a hydrate, a hydrate of a salt or a solvate thereof.

2. The compound as claimed in claim 1 ,

in which

R 1 and R 2 are attached to adjacent phenyl ring atoms and together with the two ring carbon atoms form a 5- or 6-membered saturated ring which may contain one or two oxygen atoms and which may be mono- or disubstituted, independently of one another, by methyl which may be substituted by hydroxyl, (C 1 –C 4 )-alkoxy or phenyl; fluorine; or chlorine;

R 3 represents hydrogen or chlorine

and

R 4 represents (C 2 –C 4 )-alkenyl or (C 1 –C 4 )-alkyl, where alkyl may be substituted up to two times, independently of one another, by halogen, trifluoromethyl, trifluoromethylthio, (C 3 –C 7 )-cycloalkyl, hydroxyl, —CO—NH—R 6 , (C 1 –C 4 )-alkoxy, (C 1 –C 4 )-alkoxycarbonyl, (C 2 –C 4 )-alkenyl, (C 6 –C 10 )-aryl or 5- or 6-membered heteroaryl having up to three heteroatoms selected from the group consisting of N, O and S,

 where

aryl and heteroaryl may be substituted up to three times, independently of one another, by halogen; trifluoromethyl; (C 1 –C 4 )-alkyl which may be substituted by carboxyl or (C 1 –C 4 )-alkoxycarbonyl; (C 1 –C 4 )-alkoxy; carboxyl; (C 1 –C 4 )-alkoxycarbonyl; nitro; cyano; or hydroxyl; and

R 6 represents hydrogen (C 1 –C 4 )-alkyl,

or a salt, a hydrate, a hydrate of a salt or a solvate thereof.

3. The compound as claimed in claim 1 ,

in which

R 1 and R 2 are attached to adjacent phenyl ring atoms and represent a group

R 3 represents hydrogen

and

R 4 represents propenyl; methyl; ethyl; or n-propyl; where the alkyl radicals may be substituted up to two times, independently of one another, by hydroxyl, methoxy, trifluoromethyl, trifluoromethylthio, fluorine, imidazolyl, pyridyl, or phenyl which for its part may be substituted by fluorine, cyano, nitro, methoxy, methoxycarbonyl (—C(O)—O—CH 3 ) or methoxycarbonylmethyl (—CH 2 —C(O)—CH 3 ); methoxycarbonyl (—C(O)—O—CH 3 ); amido (—C(O)—NH 2 ); or N-merhylamido (—C(O)—NH—CH 3 );

or a salt, a hydrate, a hydrate of a salt or a solvate thereof.

4. The compound as claimed in claim 1

in which

R 1 and R 2 are attached to adjacent phenyl ring atoms and represent a group

R 3 represents hydrogen

and

R 4 represents propenyl; methyl; ethyl; or n-propyl; where the alkyl radicals may be substituted up to two times, independently of one another, by hydroxyl, methoxy, trifluoromethyl, trifluoromethylthio, fluorine, imidazolyl, optionally methyl-substituted thiazolyl, pyridyl, or phenyl which for its part may be substituted by fluorine, cyano, nitro, methoxy, methoxycarbonyl (—C(O)—O—CH 3 ) or methoxycarbonylmethyl (—CH 2 —C(O)—O—CH 3 ); methoxycarbonyl (—C(O)—O—CH 3 ); amido (—C(O)—NH 2 ); or N-methylamido (—C(O)—NH—CH 3 );

or a salt, a hydrate, a hydrate of a salt or a solvate thereof.

5. The compound as claimed in claim 1

in which

R 1 and R 2 are attached to adjacent phenyl ring atoms and represent a group

R 3 represents hydrogen

and

represents methyl; ethyl; or n-propyl; where the alkyl radicals may be substituted up to two times, independently of one another, by hydroxyl, trifluoromethyl, trifluoromethylthio, fluorine, imidazolyl, optionally methyl-substituted thiazolyl, phenyl which is substituted by cyano, nitro, methoxycarbonyl (—C(O)—O—CH 3 ) or methoxycarbonylmethyl (—CH 2 —C(O)—O—CH 3 ); or amido (—C(O)—NH 2 );

or a salt, a hydrate, a hydrate of a salt or a solvate thereof.

6. A process for preparing compounds of the formula (I) as defined in claim 1 , characterized in that

a compound of the formula (II)

 in which

the radicals R 1 , R 2 and R 3 are as defined in claim 1 ,

is reacted with a compound of the formula (III)

R 4 —X  (III)

 in which

R 4 is as defined in claim 1 and

X represents a leaving group.

7. A pharmaceutical composition comprising at least one compound of the formula (I) as defined in claim 1 and at least one further auxiliary.

8. A method for the treatment of disorders of the cardiovascular system (cardiovascular disorders) comprising administering an effective amount of a compound of the formula (I) as defined in claim 1 wherein the cardiovascular disorders consists of stable and unstable angina pectoris and atrial fibrillation.

Assignments (1)
MERGER Recorded Jan 12, 2010
From: BAYER HEALTHCARE AG
To: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT
Reel/Frame 023769/0122 →